Diaceutics and IQM Redefine HCP Engagement with Real-Time, AI-Powered Diagnostic Audiences
Pharma marketers gain precision, speed, and compliance with award winning demand-side innovation and next-gen audience intelligence
Belfast, UK and New York, NY — November 10, 2025 — Diaceutics, the leader in AI driven diagnostic and genomic data for smarter HCP identification, today announced a breakthrough integration with IQM Advertising Corporation, the global media buying platform empowering advertisers in the most regulated verticals to use and enhance their data to make better ad buying decisions. This partnership unlocks a first of its kind capability: real-time activation of diagnostic-informed HCP audiences across IQM’s intelligent media infrastructure.
Together, Diaceutics and IQM are challenging the status quo of healthcare marketing where outdated claims data, fragmented insights, and rigid compliance models still dominate. By fusing Diaceutics’ clinically validated diagnostic signals with IQM’s proprietary, AI powered audience engine, the two companies are delivering a new frontier in precision HCP engagement: faster, smarter, and built for pharmaceutical grade compliance.
“IQM’s infrastructure is built from the ground up to solve the toughest targeting and compliance challenges in healthcare,” said Scott Phillips, VP, Real World Data at Diaceutics. “When you layer in real time diagnostic triggers, signals grounded in patient testing and treatment decisions you move from broad targeting to precision at the point of care. That’s where behavior changes, and that’s where therapy adoption accelerates.”
The integration makes Diaceutics catalog of hundreds of pre-built, diagnostically driven audience segments available within IQM’s platform spanning chronic conditions like diabetes and cardiovascular disease, biomarker-specific oncology pathways (e.g., EGFR, HER2, PD-L1), and even hard-to-reach rare disease populations.
These advanced segments allow pharma marketers to trigger campaigns in real-time based on diagnostic or lab events versus months old claims data. Notably, marketers have the ability to engage HCPs in the moment of clinical relevance, when treatment decisions are being made and identify hidden treaters actively managing patients invisible to traditional targeting models.
“The speed from claims data to activation is one of the strongest indicators of intent,” said Tony Sherry, GM Healthcare Lead at IQM. “Now that we have access to lab data, we can identify when a physician orders a lab for a patient — allowing us to engage the HCP proactively, even before a diagnosis is made or a prescription is written.”
Ultimately, this integration optimizes campaigns with AI-driven precision, without sacrificing regulatory rigor. A first-ever for the industry at large. Together, IQM and Diaceutics are turning real-time diagnostic insights into actionable intelligence that moves as fast as medicine itself.
“IQM was built to solve the hardest problems in healthcare advertising – precision, compliance and speed,” said Kris Qiu, CEO of IQM. “Partnering with Diaceutics takes that mission even further. We can now combine real-time clinical intelligence with our robust infrastructure, giving pharma and healthcare marketers a first-ever ability to act on clinically dynamic data at programmatic speed with pharmaceutical-grade compliance.”
This partnership between IQM and Diaceutics underscores the next era of healthcare marketing is here and driving intelligence, adaptability and responsibly precise data.
For more information visit www.iqm.com
About Diaceutics
Diaceutics exists to ensure every patient gets the right test and the right therapy at the right time. For over 20 years, we’ve partnered with the world’s leading pharma and biotech companies to close the gap between diagnostics and therapy adoption. Our platform and solutions are built on one of the most comprehensive real-world diagnostic data sets in the industry enabling our partners to commercialize with precision, at scale.
About IQM
IQM is a global media buying platform that empowers political, healthcare and other specialty advertisers in highly regulated verticals to use and enhance their data to make better ad buying decisions.
Their platform enables advertisers to construct precise audience segments that align seamlessly with their desired target audience base, using their own data, top-tier third-party data sources, and IQM’s proprietary AI-driven audience intelligence engine. This leads to more accurate forecasting, budgeting and targeting, as well as delivering campaigns that perform better across screens and formats.
IQM was recently honored with the Best Demand-Side Platform award at the 2025 MarTech Breakthrough Awards and the Best Demand-Side Technology award at the 2025 AdExchanger Awards, highlighting its leadership in innovation and excellence in programmatic advertising.
For more information, visit www.iqm.com
